New combo therapy aims to tackle Hard-to-Treat myeloma

NCT ID NCT07455851

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 4 times

Summary

This early-phase study tests a new experimental drug, REGN17372, combined with another drug called linvoseltamab in people with relapsed or refractory multiple myeloma (cancer that has returned or stopped responding to treatment). The main goals are to check safety, find the best dose, and see if the combination shrinks tumors better than linvoseltamab alone. About 150 participants will take part, and the study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN17372 (an experimental bispecific antibody) combined with linvoseltamab (another bispecific antibody)
What this could lead to: If successful, this combination could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early (first-in-human) trial, so safety and effectiveness are not yet known. Side effects may occur, and the combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Contacts and locations

Locations

Alfred Hospital
RECRUITING

Melbourne, Victoria, 3004, Australia
Evangelismos General Hospital
RECRUITING

Athens, Attica, 10676, Greece
Illawarra Cancer care centre, Wollongong Hospital
RECRUITING

Wollongong, New South Wales, 2500, Australia
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
Prince of Wales Hospital
RECRUITING

Randwick, New South Wales, 2031, Australia
Royal Adelaide Hospital
RECRUITING

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.